Title for MeetingAbstracts
Alphabetical listing of titles
-
A year-long, randomized, controlled clinical trial of a carrageenan gel as a vaginal microbicide: Acceptability of gel and applicator use.
-
A year-long, randomized, controlled clinical trial of a carrageenan gel as a vaginal microbicide: Effect on reproductive tract infection (RTI) rates.
-
A year-long, randomized, controlled clinical trial of a carrageenan gel as a vaginal microbicide: Incidence of irritation and genital lesions.
-
A youth funding scheme for encouraging youth involvement and facilitating youth networking in Hong Kong.
-
A Zululand industry response to the needs of HIV/AIDS infected and affected employees and their families.
-
A, randomised, controlled trial of subcutaneous interleukin-2 (SC IL-2) plus antiretroviral therapy (ART) versus ART alone in patients and CD4+ cell counts >/= 350/mm3.
-
A-170568 Analogs: a Novel Series of Fluoro-2-Pyridones.
-
A-B-O BLOOD GROUPS AND HIV-1 INFECTION.
-
A-Streptococcal Tonsillopharyngitis: 5-Day Cefuroxime axetil vs. 10-Day Penicillin Treatment. Results According to Childrens Age and Incidence of Poststreptococcal Sequelae.
-
A. fumigatus Induces Amphotericin B (AmB) Tolerance and Inhibits AmB Induced Cytokine Release.
-
A.I.D.S. The development of school board policy on sensitive issues.
-
A.L.I.A.'s Psychological Service "Eduardo Portello Perez" for HIV/AIDS or CRA patients.
-
A.S.P.A. : A Constant example of commitment for prevention.
-
A.S.P.A. fighting AIDS through prevention for 13 years.
-
A4-drug including nelfinavir ( NFV ) and a non-nucleoside reverse transcriptase inhibitor ( NNRTI ) has a transient efficacy in highly experienced patients with prolonged prior protease inhibitor therapy.
-
AA PILOT STUDY OF SAQUINAVIR-SGC (SQV) AND LOPINAVIR /RITONAVIR (LPV/R) TWICE DAILY IN PROTEASE INHIBITOR (PI) NAIVE HIV+ INDIVIDUALS: PROTEASE INHIBITOR CONCENTRATIONS AND WEEK 24 RESULTS.
-
AAEU on IML-2: a new space hardware for experiments using aquatic animals.
-
AAV-Mediated Gene Transfer for Hemophilia: Problems and Prospects.
-
AAV-mediated transduction of an anti-HIV-1 gag ribozyme in hematopoietic stem cells: towards gene therapy of AIDS.
-
Abacavir (1592, ABC) in protocol CNAB 2002, provides effective, long-term, 72 week, art for patients on triple therapy regimens.
-
Abacavir (1592, ABC) pharmacokinetics/pharmacodynamics (PK/PD) from monotherapy dosing in antiretroviral naive HIV-1-infected patients.
-
Abacavir (1592, ABC) population pharmacokinetics (PK) from a phase II dose-ranging trial in HIV-1-infected adults.
-
Abacavir (1592, ABC) prevents spread of HIV-1 in brain tissue of SCID mice with HIV-1 encephalitis.
-
Abacavir (ABC) and efavirenz (EFV) pharmacokinetics (PK) in adefovir (ADV)-containing salvage regimens.
-
Abacavir (ABC) has a similar safety profile when administered once daily (OAD) or twice daily (BID) in combination with lamivudine (3TC) and efavirenz (EFV) once daily to antiretroviral therapy (ART)-naive, HIV-infected adults.
-
Abacavir (ABC) Once Daily (OAD) plus Lamivudine (3TC) OAD in Combination with Efavirenz (EFV) OAD is Well-Tolerated and Effective in the Treatment of Antiretroviral Therapy (ART) Naive Adults with HIV-1 Infection (ZODIAC Study: CNA30021).
-
Abacavir /efavirenz /adefovir salvage regimen for refractory HIV disease.
-
Abacavir and tenofovir combination therapy in clinical practice.
-
Abacavir induced diabetes mellitus due to severe beta cell dysfunction and insulin resistance.
-
Abacavir systemic clearance in children is highly influenced by glucuronidation phenotype.